Success Stories: EB-1A Petition Approved in Less Than a Month for Postdoctoral Fellow from China in the Field of Oncology (PP Upgrade, No RFE)

Client’s Testimonial:

“选择Wegreened非常省心，自己认真写完Research Summary, 剩下的事情就基本上由律师完成。律师起草的推荐信和PL，我没有做大的改动。整个申请过程中律师非常负责，帮我纠正了多个小错误；在是不是PP，何时PP等关键问题上，律师也给了我很好的建议。总而言之，该律所做事可靠，值得信赖。”

“Choosing Wegreened to assist with filing my petition saved me a lot of worries. I only needed to focus on writing my research summary and the attorney basically took charge of the rest of the work. I did not make any major revisions to the recommendation letters and the Petition Letter written by the attorney. During the process of preparing my petition, the attorney was very responsible and helped correct many of my mistakes. The attorney also advised me on some crucial points, such as what Premium Processing is and when to use the Premium Processing service. To sum up, the law firm is reliable and trustworthy.”

On December 16^th, 2016, we received another EB-1A (Alien of Extraordinary Ability) approval for a Postdoctoral Fellow in the Field of Oncology (Approval Notice).

General Field: Oncology

Position at the Time of Case Filing: Postdoctoral Fellow

Country of Origin: China

Service Center: Texas Service Center (TSC)

State of Residence at the Time of Filing: Georgia

Approval Notice Date: December 16^th, 2016

Processing Time: 25 Days (Premium Processing Requested)

Case Summary:

With a Ph.D. in Immunology obtained from a top university in his birth country of China, our client boasts many years of experience researching the field of oncology. His work has resulted in various benefits for the United States, most of which are related to the study of genes and molecular regulations and the mechanisms that affect them. When he approached North America Immigration Law Group (WeGreened.com) to help him file an EB-1A (Alien of Extraordinary Ability) petition, we thoroughly reviewed his credentials to be sure that we could build a strong case for him. Once we confirmed that we could, we started the process of putting together his EB-1A petition.

Presenting our client’s achievements:

EB-1A is upheld by a very high standard of law and not everyone who files an I-140 petition under this category obtains case approval. We knew that we had to be very meticulous in presenting the many benefits our client’s work has to the US. We did this by detailing his citation count, publication record, and peer review experience. At the time of filing, our client’s work had gathered 148 citations, he had published 18 articles, and he had conducted 45 peer reviews for scientific journals. These figures proved the importance of our client’s findings not just to the nation as a whole but to other researchers who are also progressing the important field of oncology.

Alongside this evidence were six recommendation letters provided by other experts in the field. These letters briefly discussed our client’s research and strongly advocated for the approval of his EB-1A petition. According to one of our client’s recommenders: “Not only does his record of research, considered both in general and in detail, speak for itself, but progress in his area of expertise, molecular immunology, is of immediate consequence to the nation’s healthcare system.”

Because our client chose to upgrade his case to Premium Processing (PP) not long after it was filed, the USCIS only spent a total of 25 days adjudicating his case before granting their approval. We are pleased that they did not issue a Request for Evidence (RFE), and we congratulate our client for moving a step closer to green card success.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 47,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our approved cases grew from 600 in 2013 to over 47,000 in 2023.